3,4,4a,6,7,8,8a-heptahydro-1H-isochromen

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,4,4a,6,7,8,8a-heptahydro-1H-isochromen
• 英文别名: heptahydro-1H-isochromen；octahydro-1H-isochromene；octahydroisochromene；trans-3-Oxabicyclo[4.4.0]decane；3,4,4a,5,6,7,8,8a-octahydro-1H-isochromene
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: LALXVXZHYIIWQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,3,4,4a,5,6,8,8a-Octahydroisochromen-7-one 在 Ni loaded on γ-Al₂O₃ 作用下， 200.0 ℃ 、3.0 MPa 条件下， 以93 %的产率得到3,4,4a,6,7,8,8a-heptahydro-1H-isochromen
  参考文献：
  名称：

  CN115160210

  摘要：

  公开号：

文献信息

• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• [EN] NON-SYMMETRICAL GELLING AGENT<br/>[FR] AGENT DE GELIFICATION NON SYMETRIQUE
  申请人：APPLIED NANO SYSTEMS B V

  公开号：WO2005047231A1

  公开（公告）日：2005-05-26

  The present invention relates to a novel trisubstituted cyclic thickener or gelator. The present invention further relates to a method for thickening or gelating a solution comprising the use of such a gelator or thickener. A gelator or thickener according to the invention may for instance be used for pharmaceutical or cosmetic purposes. It may further be used as a support material in chromatographic materials or catalytically active materials.

  本发明涉及一种新型的三取代环状增稠剂或凝胶剂。本发明还涉及一种利用该凝胶剂或增稠剂增稠或凝胶化溶液的方法。根据本发明的凝胶剂或增稠剂可能用于制药或化妆品目的。它还可以用作色谱材料或催化活性材料的支撑材料。
• Gelling agents
  申请人：Applied NanoSystems B.V.

  公开号：EP1364941A1

  公开（公告）日：2003-11-26

  The invention relates to a novel class of gelling agents, to a process of preparing said agents, to the use of said agents to prepare gels, and to the gels thus obtained. A gelling agent or thickener according to the invention comprises a rigid core which is functionalized with three amino acid ester or amide groups by means of an amide or urea linkage. It may be used to gelate or thicken numerous solvents.

  该发明涉及一种新型凝胶剂类别，一种制备该剂的方法，使用该剂来制备凝胶，以及由此获得的凝胶。根据该发明，一种凝胶剂或增稠剂包括通过酰胺或脲键与三个氨基酸酯或酰胺基团功能化的刚性核心。它可以用于凝胶或增稠许多溶剂。
• [EN] INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF<br/>[FR] INHIBITEURS DE LA KALLIKRÉINE PLASMATIQUE ET UTILISATIONS ASSOCIÉES
  申请人：DYAX CORP

  公开号：WO2019028362A1

  公开（公告）日：2019-02-07

  Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  本文提供了抑制pKal的化合物，pKal是一种丝氨酸蛋白酶，其活性负责蛋白酶解切激肽原并生成强效的血管舒张剂和促炎肽布雷金因，这可能导致疼痛和令人痛苦的炎症发作（例如水肿）。还提供了包含这些化合物的药物组合物和试剂盒，以及使用这些化合物在受试者中治疗pKal相关疾病和紊乱（例如水肿）的方法，通过给予本文所述的化合物和/或组合物。
• Fluorine-Containing Sulfonic Acid Salt, Fluorine-Containing Sulfonic Acid Salt Resin, Resist Composition, and Pattern Forming Method Using Same
  申请人：Central Glass Company, Limited

  公开号：US20150198879A1

  公开（公告）日：2015-07-16

  Disclosed is a fluorine-containing sulfonic acid salt resin having a repeating unit represented by the following general formula (3). In the formula, each A independently represents a hydrogen atom, a fluorine atom or a trifluoromethyl group, and n represents an integer of 1-10. W represents a bivalent linking group, R 01 represents a hydrogen atom or a monovalent organic group, and M + represents a monovalent cation. A resist composition containing this resin is further superior in sensitivity, resolution and reproducibility of mask pattern and is capable of forming a pattern with a low LER.

  本公开了一种含氟磺酸盐树脂，其具有以下通用式（3）所代表的重复单元。在该式中，每个A独立地表示氢原子、氟原子或三氟甲基基团，n表示1-10的整数。W表示二价连接基团，R01表示氢原子或一价有机基团，M+表示一价阳离子。含有该树脂的抗蚀组合物在感光性、分辨率和掩膜图案的重现性方面更加优越，并且能够形成具有较低LER的图案。